NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication
titled “Effects of Wearable Transcutaneous Electrical Nerve
Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the
Journal of Pain Research. The article is available online at the
The article reports an intention-to-treat analysis of a
double-blind, randomized, sham-controlled trial that compared
3-months of at-home treatment with a standard (active) or low dose
(sham) Quell device in 119 subjects with fibromyalgia.
Note: The use of Quell for fibromyalgia is
investigational and has not been cleared or approved by the U.S.
Food and Drug Administration (FDA).
Fibromyalgia is a common form of chronic pain that is also
accompanied by fatigue, sleep, cognitive and mood disturbances. It
affects an estimated 2 to 6 percent of the U.S. population (5 to 15
million people) and is most often diagnosed between the ages of 30
and 50. The cause of fibromyalgia remains unclear, but scientific
studies point to abnormalities in the way the brain processes
normal sensations and pain. Although several drugs are FDA approved
for managing fibromyalgia pain, there is an unmet need for safe and
effective non-pharmacological treatments.
Quell is an advanced, non-invasive, nerve stimulation device
that is covered by 18 U.S. utility patents. It is the only wearable
neurostimulator that is enabled by a custom designed microchip that
provides precise, high-power nerve stimulation in a form factor the
size of a credit card. Quell utilizes position and motion sensing
to automatically adjust stimulation for an optimal patient
experience both day and night. The device supports Bluetooth® low
energy (BLE) to communicate with the Quell app, which is available
for iOS and Android mobile devices. Quell is currently indicated
for symptomatic relief and management of chronic lower extremity
(knee, foot and leg) pain. It is available over-the-counter for
this use. Visit QuellRelief.com for more information.
NeuroMetrix is an innovation-driven company focused on the
development and global commercialization of non-invasive medical
devices for the diagnosis and treatment of pain and neurological
disorders. The Company has three commercial products. DPNCheck® is
a diagnostic device that provides rapid, point-of-care detection of
peripheral neuropathies. ADVANCE® is a diagnostic device that
provides automated, in-office nerve conduction studies for the
evaluation of entrapment neuropathies. Quell® is a wearable
neurostimulation device indicated for treatment of lower extremity
chronic pain. For more information, visit www.NeuroMetrix.com.
Source: NeuroMetrix, Inc.
Thomas T. HigginsSVP and Chief Financial
Historical Stock Chart
From Nov 2021 to Dec 2021
Historical Stock Chart
From Dec 2020 to Dec 2021